glp 1 pipeline GLP-1 Update: May 2026 - Prime Therapeutics Insulin and SGLT inhibitors dominate
Description
The GLP-1 Receptor Agonist market size is expected to reach $18.32 billion in 2030 at a CAGR of 5.4%, driven by rising prevalence of diabetes.
Note: Anti-Obesity GLP-1s Wegovy and Zepbound, Anti-Diabetes GLP-1s Ozempic and Mounjaro Source: IQVIA MAAS Patient Behavior Library Tool
Serena Williams recently shared that she started taking the GLP-1 drug Zepbound after having her two children
By supporting digestive function and gut balance, this formula aids in nutrient absorption, helping your body naturally aid burn excess fat
What is Retatrutide
Introduction: Revolutionizing Healthcare in Dallas, Little Elm/Frisco, TX Semaglutide vs
